For example, the SELECT trial focused on obese individuals without diabetes; AMPLITUDE‐O included a proportion of patients receiving SGLT2 inhibitors, introducing the possibility of synergistic effects; and ELIXA specifically recruited patients with recent acute coronary syndrome.5, 7, 14. This evidence concerns the gene SLC5A2 and acute coronary syndrome.